Clinical trial NCT00781560: Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal
Official title: A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperlipidemia
Keywords: Hyperlipidemia
Chinese National Adult Lipid Treatment Guideline (2007)
Crestor®
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-10-29
Enrollment: 2575
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who has been diagnosed as hypercholesterolemia and decided by physician to use Crestor® 5mg or 10mg or other regimens (TLC or other lipid-lowering agents)

Brief summary: This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg


Eligibility criteria: Inclusion Criteria:

* Diagnosed as dyslipidemia by doctors
* Having lipids test and record within one months
* Diagnosed as hypercholesterolemia or mixed dyslipidaemias and has been prescribed Crestor® 5mg or 10mg

Exclusion Criteria:

* Unable or unwilling to provide the Inform Consent

Primary outcomes:
measure: the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists
timeFrame: 1 time
measure: the control rate of patients reaching target LDL-C level
timeFrame: 8 weeks
Secondary outcomes:
measure: the percent change from baselines in TC, TG, HDL-C
timeFrame: 8 weeks
measure: the percentage of hyperlipidemia patients in different risk categories who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007)
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Research Site
state: Beijing
city: Chenzhen
country: China
facility: Research Site
state: Guangdong
city: Guangzhou
country: China
facility: Research Site
state: Guangdong
city: Harbin
country: China
facility: Research Site
state: Heilongjiang
city: ZhengZhou
country: China
facility: Research Site
state: Henan
city: Nanjing
country: China
facility: Research Site
state: Jiangsu
city: Shenyang
country: China
facility: Research Site
state: Liaoning
city: Jinan
country: China
facility: Research Site
state: Shandong
city: Qingdao
country: China
facility: Research Site
state: Shandong
city: Shanghai
country: China
facility: Research Site
state: Shanghai
city: Xi'an
country: China
facility: Research Site
state: Shanxi
city: Chengdu
country: China
facility: Research Site
state: Sichuan
city: Tianjin
country: China
facility: Research Site
state: Tianjin
city: Hangzhou
country: China
facility: Research Site
state: Zhejiang
city: Ningbo
country: China
facility: Reseearch Site
state: Zhejiang
Study officials:
affiliation: Astrazeneca China R&D
name: Karen Atkin
role: STUDY_DIRECTOR
affiliation: Fudan University
name: Zhu Junren
role: PRINCIPAL_INVESTIGATOR
References: